CN114358939B - Monitoring method and device for hot spot information in pharmaceutical industry, electronic equipment and storage medium - Google Patents
Monitoring method and device for hot spot information in pharmaceutical industry, electronic equipment and storage medium Download PDFInfo
- Publication number
- CN114358939B CN114358939B CN202111665276.8A CN202111665276A CN114358939B CN 114358939 B CN114358939 B CN 114358939B CN 202111665276 A CN202111665276 A CN 202111665276A CN 114358939 B CN114358939 B CN 114358939B
- Authority
- CN
- China
- Prior art keywords
- information
- hotspot information
- hotspot
- medicine
- preset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000012544 monitoring process Methods 0.000 title claims abstract description 45
- 238000003860 storage Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 202
- 229940079593 drug Drugs 0.000 claims abstract description 63
- 238000012827 research and development Methods 0.000 claims description 14
- 238000011161 development Methods 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 238000004590 computer program Methods 0.000 claims description 10
- 229940042040 innovative drug Drugs 0.000 claims description 6
- 238000012806 monitoring device Methods 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 6
- 238000004891 communication Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000009960 carding Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940125005 clesacostat Drugs 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P90/00—Enabling technologies with a potential contribution to greenhouse gas [GHG] emissions mitigation
- Y02P90/30—Computing systems specially adapted for manufacturing
Landscapes
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The invention provides a monitoring method, a device, electronic equipment and a storage medium for hot spot information in the pharmaceutical industry, wherein the method comprises the following steps: acquiring medicine information of a target medicine enterprise; based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set; the method, the device, the electronic equipment and the storage medium provided by the invention can clearly, accurately and completely comb the product pipelines of the medicine innovation marketing enterprises, can monitor and foresight predict the relevant hot spot information of the medicines affecting the stock price of the target innovation medicine marketing enterprises in real time, and are convenient for investors to prepare correspondingly before the stock price information fluctuates severely.
Description
Technical Field
The present invention relates to the field of information monitoring technologies, and in particular, to a method and apparatus for monitoring hotspot information in the pharmaceutical industry, an electronic device, and a storage medium.
Background
Since 2015, the pharmaceutical industry of China has come to explode innovative wave. By 2021, 6 months, the medical industry of China has attracted 1.5 trillion RMB social financing for the past six years, reaching an unprecedented level. Especially, the opening of hong Kong biological medicine boards and scientific creation boards, and the non-profit medicine innovation enterprises open capital withdrawal and new financing channels. Against this background, a large number of pharmaceutical innovative enterprises have been successfully marketed, and pharmaceutical tablets have become an indispensable investment track in the secondary market.
The valuation given by the capital market for traditional pharmaceutical enterprises is often based on its financial base, i.e., sales revenue and net profit, etc. The financial index is secret of enterprises and is not disclosed externally, investors can only follow up investment according to the public announcement of the enterprises on the market, and the prior advantage of asymmetric information is difficult to occur.
Disclosure of Invention
The invention provides a monitoring method, a device, electronic equipment and a storage medium for hot spot information in the medicine industry, which are used for solving the problems that a product pipeline of an innovative medicine marketing enterprise cannot be monitored, and medicine related hot spot events and time affecting stock price fluctuation are predicted in advance in the prior art.
The invention provides a monitoring method of hot spot information in the pharmaceutical industry, which comprises the following steps:
acquiring medicine information of a target medicine enterprise;
Based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to the second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set.
According to the monitoring method of the hot spot information in the pharmaceutical industry provided by the invention, the acquisition of the medicine information of the target medicine enterprise comprises the following steps:
Acquiring a medical enterprise which is marketed as a target medical enterprise based on a pre-constructed medical enterprise dictionary;
acquiring medicine information in research and development of a target medicine enterprise and medicine information on the market;
And acquiring core medicine information of a target medicine enterprise based on the medicine information in research and development and the medicine information on the market.
According to the monitoring method of the hot spot information in the pharmaceutical industry, which is provided by the invention, the core medicine information comprises the following steps:
innovative drug information acquired based on drug information in development;
And acquiring market sales information of the marketed medicines, and acquiring medicine information with the sales ratio exceeding a preset threshold value based on the market sales information of the medicines.
According to the method for monitoring the hot spot information in the pharmaceutical industry provided by the invention, if the hot spot information element belongs to a first preset hot spot information set, the hot spot information element is marked with the current time, and the method comprises the following steps:
Acquiring a hotspot information element in first preset hotspot information based on a preset time interval, and marking a target hotspot information element according to the time acquired by the target hotspot information element;
According to the method for monitoring the hot spot information in the pharmaceutical industry provided by the invention, if the hot spot information element belongs to a second preset hot spot information set, a predicted time increment value corresponding to a target hot spot information element is obtained, and the hot spot information element is marked based on the starting time and the predicted time increment value of the hot spot information element in the second preset hot spot information set, and the method comprises the following steps:
Obtaining the starting time of the hot spot information element in the second preset hot spot information based on the marking time of the hot spot information element in the first preset hot spot information;
Obtaining similar medicine information of the target medicine information, and obtaining a predicted time increment value of a heat point information element in second preset heat point information based on historical data of the similar medicine information time increment value;
And marking the hot spot information element in the second preset hot spot information based on the starting time and the predicted time increment value of the hot spot information element in the second preset hot spot information.
According to the monitoring method of the hot spot information in the pharmaceutical industry, the hot spot information element in the first preset hot spot information is at least one element in hot spot events of transaction, application of clinic, starting of clinical test, application of marketing and influence on sales;
And the hot spot information element in the second preset hot spot information is at least one element of approval of clinic, ending of clinic test and approval of marketing.
The invention provides a monitoring method of hot spot information in the pharmaceutical industry, which is characterized by further comprising the following steps:
Pushing the hotspot information element and the related information thereof in the first preset hotspot information at the time marked currently.
And pushing the hotspot information elements and the associated information thereof in the second preset hotspot information in the form of calendar marks.
The invention also provides a monitoring device for hot spot information in the pharmaceutical industry, which comprises:
an information acquisition module: acquiring medicine information of a target medicine enterprise;
and the information monitoring module: based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to the second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set.
The invention also provides an electronic device, which comprises a memory, a processor and a computer program stored in the memory and capable of running on the processor, wherein the steps of the monitoring method for hot spot information in any one of the above medicines are realized when the processor executes the computer program.
The present invention also provides a non-transitory computer readable storage medium having stored thereon a computer program which, when executed by a processor, implements the steps of the method of monitoring pharmaceutical industry hotspot information as described in any of the above.
The monitoring method, the device, the electronic equipment and the storage medium for the hot spot information in the medicine industry provided by the invention can clearly, accurately and completely comb the product pipelines of the medicine innovation marketing enterprises, monitor and foresight predict the relevant hot spot information of the medicines affecting the stock price of the target innovation medicine marketing enterprises in real time, and are convenient for investors to prepare correspondingly before the stock price information fluctuates severely.
Drawings
In order to more clearly illustrate the invention or the technical solutions of the prior art, the following description will briefly explain the drawings used in the embodiments or the description of the prior art, and it is obvious that the drawings in the following description are some embodiments of the invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a flow chart of a method for monitoring information of hot spots in the pharmaceutical industry;
fig. 2 is a schematic structural diagram of a monitoring device for hot spot information in the pharmaceutical industry according to the present invention;
fig. 3 is a schematic structural diagram of an electronic device provided by the present invention.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings, and it is apparent that the described embodiments are some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The invention will now be described in detail with reference to the drawings and specific examples.
Since 2015, the pharmaceutical industry of China has come to explode innovative wave. By 2021, 6 months, the medical industry of China has attracted 1.5 trillion RMB social financing for the past six years, reaching an unprecedented level. Especially, the opening of hong Kong biological medicine boards and scientific creation boards, and the non-profit medicine innovation enterprises open capital withdrawal and new financing channels. Against this background, a large number of pharmaceutical innovative enterprises have been successfully marketed, and pharmaceutical tablets have become an indispensable investment track in the secondary market.
The valuation given by the capital market for traditional pharmaceutical enterprises is often based on its financial base, i.e., sales revenue and net profit, etc. The financial index is secret of enterprises and is not disclosed externally, investors can only follow up investment according to the public announcement of the enterprises on the market, and the prior advantage of asymmetric information is difficult to occur.
For innovative medicine marketing enterprises which come into the market in recent years, most of the enterprises are loss enterprises, the research and development investment is huge, enterprise valuations are often irrelevant to sales income, and the valuations given by investors are mainly from innovative product pipelines. However, the development activities of pharmaceutical innovation enterprises have high uncertainties, and the possibility of unexpected or failed development exists. The science wound board allows daytime fluctuation to be +/-20%, and the hong Kong capital market does not limit the daytime stock price fluctuation interval. The stock price of the market enterprises always has severe fluctuation along with the disclosure of the message surface, and the investment price has great influence on the investors.
In summary, there is a need to clearly, accurately and completely comb product pipelines of pharmaceutical innovation marketing enterprises, and to monitor and predict real-time relevant hot spot information of medicines affecting stock prices of target innovation pharmaceutical marketing enterprises.
Fig. 1 is a flow chart of a method for monitoring hot spot information in pharmaceutical industry, as shown in fig. 1, the method includes:
step 110: acquiring medicine information of a target medicine enterprise;
Here, the target pharmaceutical enterprise is a pharmaceutical enterprise that has been marketed, and specifically, the pharmaceutical enterprise that has been marketed may be obtained as the target pharmaceutical enterprise based on a pre-constructed pharmaceutical enterprise dictionary;
in detail, the pre-constructed pharmaceutical enterprise dictionary at least includes an enterprise name and an enterprise marketing type, for example:
| enterprise name | Type of business on the market |
| Beijing health (control stock) limited enterprises | Harbor strand |
| Shenzhen City multiple light science and technology share limited enterprises | A strand |
| Guangzhou Taili biological medicine technology limited enterprises | Not on the market |
For new pharmaceutical marketing enterprises that come into the market in recent years, the investors give their valuations mainly from their new product pipelines. However, the research and development activities of the medicine innovation enterprises have higher uncertainty, and the possibility of unexpected or research and development failure exists, so that the stock price of the marketing enterprises often fluctuates severely along with the disclosure of the message surface, and the investment income is greatly influenced;
Therefore, clear, accurate and complete carding of product pipelines of pharmaceutical innovation marketing enterprises is needed; the product pipeline of the pharmaceutical enterprise comprises drug information under development and drug information on the market.
In consideration of thousands of production lines of large-scale pharmaceutical enterprises on the market, and various research and development types of medicines including innovative medicines, imitated medicines, biological analogues and the like can be covered in the production lines, wherein the innovative medicines are medicines which are independently researched and developed by target pharmaceutical enterprises and have independent intellectual property rights, the biological analogues are biological products which are produced by the target pharmaceutical enterprises and are highly similar to biological patent medicines, and the imitated medicines are substitute medicines which are produced by the target pharmaceutical enterprises and have the same active ingredients, dosage forms, administration routes and therapeutic effects as imitated medicines; however, if the hot spot information related to any medicine does not exist, the stock price of the target medicine enterprise is greatly influenced;
therefore, based on the drug information in research and development and the drug information on the market, core drug information of a target pharmaceutical enterprise is acquired; the core medicine information is medicine information which has great influence on stock price fluctuation of a target medicine enterprise;
considering, on the one hand, for innovative pharmaceutical marketing enterprises that come into the market in recent years, the investors give them an estimate mainly from their innovative product pipelines; on the other hand, the main medicine of the target medicine enterprise is not an innovative medicine, and at present, the main medicine of large-scale domestic medicine enterprises mainly imitates medicines;
Thus, the core drug comprises: innovative drug information acquired based on drug information in development; acquiring market sales information of the marketed medicines, and acquiring medicine information with the sales ratio exceeding a preset threshold value based on the market sales information of the medicines;
In detail, in one aspect, a method for obtaining innovative drug information based on drug information under development includes:
drug information in domestic research and development can be acquired based on CDE/ChiCTR, and drug information, enterprise information, indication information and research and development stage information can be extracted from the drug information;
The medicine information, the enterprise information, the indication information and the research and development stage information can also be obtained from files such as a marketing company file, a patent and the like based on clinical registration platforms of various countries, papers published by enterprises, announcements published by enterprises and information disclosed by medicine monitoring institutions;
Based on the acquired enterprise information, matching in a pre-constructed enterprise dictionary to obtain a standard enterprise name; based on the acquired drug information, matching is performed in a pre-constructed drug dictionary including, but not limited to, drug name, drug innovation type; if the matching is not achieved, the method indicates that the medicine possibly is an innovative medicine under development, marks the medicine innovation type of the target medicine with an innovative medicine, and pushes the medicine innovation type to be audited by a worker, so that the accuracy of data is ensured; based on the acquired indication information, matching is carried out in a constructed indication dictionary to obtain a standard indication name;
Based on the above steps, product pipeline information of the target enterprise under development is acquired, for example:
| Medicine name | Enterprise name | Disease of the human body | Development stage |
| clesacostat | Pfizer | Nonalcoholic steatohepatitis | Phase II clinical |
| recifercept | Pfizer | Achondroplasia | Phase II clinical |
| Pr Lin Beirui | Wyeth(Pfizer) | Dysmenorrhea; rheumatoid arthritis; endometriosis | Phase II clinical |
| …… | …… | …… | …… |
In another aspect, a method of acquiring market sales information of a marketed drug, the sales information acquired based on the market sales information of the drug having a sales ratio exceeding a preset threshold, includes:
Acquiring a calendar year drug marketing information table based on various national drug administration official websites, such as NMPA (national drug administration: national Medical Products Administration), FDA (American food and drug administration: food and Drug Administration), EMA (European Union drug administration: european MEDICINES AGENCY), HMA (European Union drug administration: heads of MEDICINES AGENCIES), PMDA (Japanese medical device inspection and review batch agency: pharmaceuticals AND MEDICAL DEVICES AGENCY) and the like, and extracting therefrom information including but not limited to drug information, enterprise information, indication information;
Based on the acquired enterprise information, matching in a pre-constructed enterprise dictionary to obtain a standard enterprise name; obtaining standard medicine name information from a pre-constructed medicine dictionary based on the acquired medicine information; based on the acquired indication information, matching is carried out in a constructed indication dictionary to obtain a standard indication name;
Based on the above steps, the marketed product line information of the target pharmaceutical enterprise is obtained, for example:
Further, based on the drug information of the target pharmaceutical enterprise on the market, the sales information and the total sales of the target drug are obtained from the financial report of the target pharmaceutical enterprise in a preset year, wherein the preset year can be 1 year, 2 years and 5 years, and the embodiment of the invention is not particularly limited.
Based on the sales information and the total sales of the target medicines, obtaining the medicine information that the sales ratio of the target medicines exceeds a preset threshold, wherein the preset threshold can be 30%, 40% and 50%, and the embodiment of the invention is not particularly limited.
Step 120, based on the drug information, monitoring a preset hotspot information element, and if the hotspot information element belongs to a first preset hotspot information set, marking the hotspot information element with the current time; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set;
The research and development activities of the medicine innovation enterprises have higher uncertainty, the possibility of unexpected or research and development failure exists, the stock price of the marketing enterprises always has severe fluctuation along with the disclosure of the information surface, and the investment income is greatly influenced;
Therefore, on the basis of clearly, accurately and completely carding product pipelines of pharmaceutical innovation marketing enterprises, real-time monitoring and prospective prediction of the relevant hot spot information of medicines affecting the stock price of target innovation pharmaceutical marketing enterprises become vital;
Specifically, if the hotspot information element belongs to the first preset hotspot information set, the method for marking the hotspot information element with the current time includes: acquiring a hotspot information element in first preset hotspot information based on a preset time interval, and marking a target hotspot information element according to the time acquired by the target hotspot information element; the preset time interval may be 1 hour, 12 hours, or 24 hours, which is not specifically limited in the embodiment of the present invention.
If the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set, wherein the method comprises the following steps: obtaining the starting time of the hot spot information element in the second preset hot spot information based on the marking time of the hot spot information element in the first preset hot spot information; obtaining similar medicine information of the target medicine information, and obtaining a predicted time increment value of a heat point information element in second preset heat point information based on historical data of the similar medicine information time increment value; marking the hot spot information element in the second preset hot spot information based on the starting time and the predicted time increment value of the hot spot information element in the second preset hot spot information;
specifically, in this embodiment, for the development of innovative drugs, the new drug development milestone includes preclinical research-application clinic-phase I-phase II-phase III-marketing application-marketing, and in the development process of innovative drugs, the disclosure of each milestone node has a strong influence on the fluctuation of stock price, and therefore, each milestone node can be regarded as a hotspot information element; considering that, on one hand, some pharmaceutical enterprises introduce new product pipelines from other enterprises in a presence-in manner and further develop clinical trials, so that transaction information between pharmaceutical enterprises needs to be included in hotspot information elements; on the other hand, after the medicine is marketed, the sales amount and/or price of the target medicine are increased or decreased suddenly due to the influence factor of the medicine itself and/or the influence factor of the enterprise where the medicine is located and/or the influence factor of the policy, etc., so that the sales amount of the target medicine is influenced, therefore, the hot event influencing the sales needs to be included in the hot information element, for example, the event that the adverse reaction is disclosed after the target medicine is marketed, the target medicine is included in the medical insurance and/or collection, the enterprise where the target medicine is located is required GMP (Good Manufacturing Practice) for authentication, etc., which is not particularly limited in the embodiment of the present invention.
Specifically, the hotspot information element in the first preset hotspot information is at least one element in the hotspot events of transaction, application of clinic, start of clinical test, application of marketing and influence on sales;
wherein the beginning clinical trial includes, but is not limited to, beginning a phase I clinical trial, beginning a phase II clinical trial, beginning a phase III clinical trial;
The occurrence time of the hotspot element in the first preset hotspot information cannot be predicted, the target hotspot information element needs to be monitored and acquired in real time, and the target hotspot information element is marked by the acquisition time of the target hotspot information element.
In detail, presetting time intervals, and acquiring information including but not limited to hot spot information elements, medicine information and enterprise information from target enterprise official networks, official clinical registration information websites, official medicine review information websites, medicine bid purchasing websites, adverse reaction event notices disclosed by FDA/MPA and medical insurance negotiation disclosure information;
performing standardized processing on the acquired hotspot element information, and matching the hotspot element names of the standards after cleaning;
and matching the acquired medicine information and enterprise information in a pre-constructed medicine dictionary and an enterprise dictionary to obtain standard medicine names and enterprise names.
And marking the target hotspot information element by the time acquired by the target hotspot information element.
The hot spot information element in the second preset hot spot information is at least one element of approval of clinic, ending of clinic test and approval of marketing;
Wherein the ending clinical trial includes, but is not limited to, ending a phase I clinical trial, ending a phase II clinical trial, ending a phase III clinical trial;
The occurrence time of the hotspot element in the second preset hotspot information may be predicted, and the second hotspot information element may be marked based on the predicted time.
In the detailed description of the present invention,
For approval clinical, approval to market:
based on the fact that the hot spot information element in the first preset hot spot information is the marking time of applying for clinic and applying for marketing, the hot spot information element in the second preset hot spot information is the starting time of approving clinic and approving marketing respectively;
obtaining the same-class medicine information of the target medicine, wherein the same-class medicine refers to medicine with the same attribute value, and the attribute value comprises but is not limited to medicine type, innovation type and application item; the attribute value may be preset, or may be a drug attribute value that is marked in advance, and the drug attribute value is calculated based on correlation analysis to obtain a high-correlation attribute value, which is not particularly limited in the embodiment of the present invention.
Acquiring the evaluation period of each drug in the drug information set of the target drug and the attribute value; the predicted evaluation period of the target medicine is obtained according to the evaluation period of each medicine, and the predicted evaluation period of the target medicine can be the average number or the median of the evaluation periods of each medicine in the medicine information set with the same attribute value, and is not particularly limited in the embodiment of the invention; the prediction evaluation period is a prediction time increment value;
The predicted date of the approving clinic is obtained based on the starting time of the approving clinic and the predicted time increment value.
For ending the clinical trial:
Based on the marking time of each beginning clinical trial stage of the hot spot information element in the first preset hot spot information, the marking time is used as the beginning time of the corresponding ending clinical trial stage of the hot spot information element in the second preset hot spot information;
the method includes the steps of obtaining similar medicine information of a target medicine, wherein the similar medicine refers to a medicine with the same attribute value, the attribute value comprises but is not limited to indication information, clinical trial recruitment information, development area information and sponsor information, the attribute value can be preset, and the embodiment of the invention is not particularly limited.
Acquiring the test period of each drug in the drug information set of the same attribute value of the target drug under the target clinical test stage; according to the test period of each drug in the drug information set with the same attribute value under the stage of the target clinical test, the predicted test period of the target drug can be obtained based on the average number of the test period of each drug, or can be obtained based on the median of the test period of each drug, and the predicted test period is the predicted time increment value without specific limitation in the embodiment of the invention;
The end time of the target clinical trial session is obtained based on the start time of the target clinical trial session and the predicted time increment value.
Further, pushing the hot spot information elements and the associated information thereof in the first preset hot spot information at the time marked currently;
Pushing the hot spot information elements and the associated information in the second preset hot spot information in the form of calendar marks; the pushing in the form of calendar marks is information pushing in the form of labels or links on an electronic calendar.
Wherein, the related information includes but is not limited to standardized medicine information, enterprise information and texts disclosing hot spot information elements.
The following describes a monitoring device for hot spot information in the pharmaceutical industry, and the monitoring device for hot spot information in the pharmaceutical industry and the monitoring method for hot spot information in the pharmaceutical industry described below can be referred to correspondingly.
Fig. 2 is a schematic structural diagram of a monitoring device for hot spot information in the pharmaceutical industry. As shown in fig. 2, the apparatus includes:
Information acquisition module 210: acquiring medicine information of a target medicine enterprise;
The information monitoring module 220: based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set;
The device provided by the embodiment of the invention obtains the medicine information of the target medicine enterprise; based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set, clearly, accurately and completely carding a product pipeline of a medicine innovation marketing enterprise, and carrying out real-time monitoring and prospective prediction on medicine related hotspot information influencing the stock price of the target innovation medicine marketing enterprise, so that investors can prepare correspondingly before the stock price information fluctuates severely.
Fig. 3 illustrates a physical schematic diagram of an electronic device, as shown in fig. 3, where the electronic device may include: processor 310, communication interface (Communications Interface) 320, memory 330 and communication bus 340, wherein processor 310, communication interface 320 and memory 330 communicate with each other via communication bus 340. The processor 310 may invoke logic instructions in the memory 330 to perform a method of monitoring information about hot spots in the pharmaceutical industry, the method comprising: : acquiring medicine information of a target medicine enterprise; based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set;
Further, the logic instructions in the memory 330 described above may be implemented in the form of software functional units and may be stored in a computer-readable storage medium when sold or used as a stand-alone product. Based on this understanding, the technical solution of the present invention may be embodied essentially or in a part contributing to the prior art or in a part of the technical solution, in the form of a software product stored in a storage medium, comprising several instructions for causing a computer device (which may be a personal computer, a server, a network device, etc.) to perform all or part of the steps of the method according to the embodiments of the present invention. And the aforementioned storage medium includes: a usb disk, a removable hard disk, a Read-Only Memory (ROM), a random access Memory (RAM, random Access Memory), a magnetic disk, or an optical disk, or other various media capable of storing program codes.
In another aspect, the present invention also provides a computer program product comprising a computer program stored on a non-transitory computer readable storage medium, the computer program comprising program instructions which, when executed by a computer, enable the computer to perform a method of monitoring pharmaceutical industry hotspot information provided by the above methods, the method comprising: acquiring medicine information of a target medicine enterprise; based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to the second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set.
In yet another aspect, the present invention further provides a non-transitory computer readable storage medium having stored thereon a computer program which, when executed by a processor, is implemented to perform a method of monitoring hot spot information in the pharmaceutical industry provided above, the method comprising: acquiring medicine information of a target medicine enterprise; based on the medicine information, monitoring a preset hotspot information element, and marking the hotspot information element with the current time if the hotspot information element belongs to a first preset hotspot information set; if the hotspot information element belongs to the second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set.
The apparatus embodiments described above are merely illustrative, wherein the elements illustrated as separate elements may or may not be physically separate, and the elements shown as elements may or may not be physical elements, may be located in one place, or may be distributed over a plurality of network elements. Some or all of the modules may be selected according to actual needs to achieve the purpose of the solution of this embodiment. Those of ordinary skill in the art will understand and implement the present invention without undue burden.
From the above description of the embodiments, it will be apparent to those skilled in the art that the embodiments may be implemented by means of software plus necessary general hardware platforms, or of course may be implemented by means of hardware. Based on this understanding, the foregoing technical solution may be embodied essentially or in a part contributing to the prior art in the form of a software product, which may be stored in a computer readable storage medium, such as ROM/RAM, a magnetic disk, an optical disk, etc., including several instructions for causing a computer device (which may be a personal computer, a server, or a network device, etc.) to execute the method described in the respective embodiments or some parts of the embodiments.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (7)
1. The monitoring method of the hot spot information in the pharmaceutical industry is characterized by comprising the following steps of:
acquiring medicine information of a target medicine enterprise;
Based on the medicine information, monitoring preset hotspot information elements, if the hotspot information elements belong to a first preset hotspot information set, acquiring the hotspot information elements in the first preset hotspot information set based on a preset time interval, marking target hotspot information elements by the time acquired by the target hotspot information elements, and pushing the hotspot information elements and associated information thereof in the first preset hotspot information set at the time of current marking;
If the hotspot information element belongs to a second preset hotspot information set, acquiring the starting time of the hotspot information element in the second preset hotspot information set based on the marking time of the hotspot information element in the first preset hotspot information set, acquiring the same-class medicine information as the target medicine information, acquiring the predicted time increment value of the hotspot information element in the second preset hotspot information set based on the historical data of the time increment value of the same-class medicine information, marking the hotspot information element in the second preset hotspot information set based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set, and pushing the hotspot information element and related information thereof in the second preset hotspot information set in a calendar mark mode.
2. The method for monitoring hot spot information in the pharmaceutical industry according to claim 1, wherein the step of obtaining the pharmaceutical information of the target pharmaceutical enterprise includes:
Acquiring a medical enterprise which is marketed as a target medical enterprise based on a pre-constructed medical enterprise dictionary;
acquiring medicine information in research and development of a target medicine enterprise and medicine information on the market;
And acquiring core medicine information of a target medicine enterprise based on the medicine information in research and development and the medicine information on the market.
3. The method for monitoring hot spot information in the pharmaceutical industry according to claim 2, wherein the core medicine information comprises:
innovative drug information acquired based on drug information in development;
And acquiring market sales information of the marketed medicines, and acquiring medicine information with the sales ratio exceeding a preset threshold value based on the market sales information of the medicines.
4. A method for monitoring hotspot information in the pharmaceutical industry according to any one of claims 1 to 3, wherein the hotspot information element in the first preset hotspot information set is at least one element of a transaction, a clinical application, a clinical trial initiation, a market application, and a sales-influencing hotspot event;
The hotspot information element in the second preset hotspot information set is at least one element of approving a clinic, ending a clinic test and approving marketing.
5. The utility model provides a monitoring device of medicine trade hotspot information which characterized in that includes:
an information acquisition module: acquiring medicine information of a target medicine enterprise;
And the information monitoring module: based on the medicine information, monitoring preset hotspot information elements, if the hotspot information elements belong to a first preset hotspot information set, acquiring the hotspot information elements in the first preset hotspot information set based on a preset time interval, marking target hotspot information elements by the time acquired by the target hotspot information elements, and pushing the hotspot information elements and associated information thereof in the first preset hotspot information set at the time of current marking; if the hotspot information element belongs to a second preset hotspot information set, acquiring the starting time of the hotspot information element in the second preset hotspot information set based on the marking time of the hotspot information element in the first preset hotspot information set, acquiring the same-class medicine information as the target medicine information, acquiring the predicted time increment value of the hotspot information element in the second preset hotspot information set based on the historical data of the time increment value of the same-class medicine information, marking the hotspot information element in the second preset hotspot information set based on the starting time and the predicted time increment value of the hotspot information element in the second preset hotspot information set, and pushing the hotspot information element and related information thereof in the second preset hotspot information set in a calendar mark mode.
6. An electronic device comprising a memory, a processor and a computer program stored on the memory and executable on the processor, characterized in that the processor implements the steps of the method for monitoring information of hot spots in the pharmaceutical industry according to any one of claims 1 to 4 when the program is executed by the processor.
7. A non-transitory computer readable storage medium having stored thereon a computer program, wherein the computer program when executed by a processor implements the steps of the method of monitoring for pharmaceutical industry hotspot information according to any one of claims 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111665276.8A CN114358939B (en) | 2021-12-31 | 2021-12-31 | Monitoring method and device for hot spot information in pharmaceutical industry, electronic equipment and storage medium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111665276.8A CN114358939B (en) | 2021-12-31 | 2021-12-31 | Monitoring method and device for hot spot information in pharmaceutical industry, electronic equipment and storage medium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114358939A CN114358939A (en) | 2022-04-15 |
| CN114358939B true CN114358939B (en) | 2024-05-07 |
Family
ID=81104593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111665276.8A Active CN114358939B (en) | 2021-12-31 | 2021-12-31 | Monitoring method and device for hot spot information in pharmaceutical industry, electronic equipment and storage medium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114358939B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006040248A (en) * | 2004-06-23 | 2006-02-09 | Tomoaki Hirakawa | Stock investment information providing system and method |
| CN101645067A (en) * | 2008-08-05 | 2010-02-10 | 北京大学 | Method for predicting hot forum in forum collection |
| CN101763401A (en) * | 2009-12-30 | 2010-06-30 | 暨南大学 | Network public sentiment hotspot prediction and analysis method |
| CN104620275A (en) * | 2012-07-19 | 2015-05-13 | 塞弗德公司 | Remote monitoring of medical devices |
| CN109285590A (en) * | 2018-08-07 | 2019-01-29 | 广州火龙果信息科技有限公司 | A kind of inpatient adverse drug events actively monitoring and assessment warning system |
| CN112489812A (en) * | 2020-11-30 | 2021-03-12 | 北京华彬立成科技有限公司 | Drug development analysis method, drug development analysis device, electronic device, and storage medium |
| CN113724085A (en) * | 2021-07-24 | 2021-11-30 | 北京华彬立成科技有限公司 | Mining method and device for early project information, electronic equipment and storage medium |
| CN113723826A (en) * | 2021-06-11 | 2021-11-30 | 北京华彬立成科技有限公司 | Method and device for monitoring early information of imitation drugs, electronic equipment and storage medium |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009510A2 (en) * | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
-
2021
- 2021-12-31 CN CN202111665276.8A patent/CN114358939B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006040248A (en) * | 2004-06-23 | 2006-02-09 | Tomoaki Hirakawa | Stock investment information providing system and method |
| CN101645067A (en) * | 2008-08-05 | 2010-02-10 | 北京大学 | Method for predicting hot forum in forum collection |
| CN101763401A (en) * | 2009-12-30 | 2010-06-30 | 暨南大学 | Network public sentiment hotspot prediction and analysis method |
| CN104620275A (en) * | 2012-07-19 | 2015-05-13 | 塞弗德公司 | Remote monitoring of medical devices |
| CN109285590A (en) * | 2018-08-07 | 2019-01-29 | 广州火龙果信息科技有限公司 | A kind of inpatient adverse drug events actively monitoring and assessment warning system |
| CN112489812A (en) * | 2020-11-30 | 2021-03-12 | 北京华彬立成科技有限公司 | Drug development analysis method, drug development analysis device, electronic device, and storage medium |
| CN113723826A (en) * | 2021-06-11 | 2021-11-30 | 北京华彬立成科技有限公司 | Method and device for monitoring early information of imitation drugs, electronic equipment and storage medium |
| CN113724085A (en) * | 2021-07-24 | 2021-11-30 | 北京华彬立成科技有限公司 | Mining method and device for early project information, electronic equipment and storage medium |
Non-Patent Citations (2)
| Title |
|---|
| 某三级医院重点监控药品的使用情况分析;王烨;程刚;;中国当代医药(24);全文 * |
| 煤炭企业专利技术研发热点与前沿的可视化分析――以中国神华为例;周志强;景惠玲;;科技促进发展;20200720(07);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114358939A (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lesser | The effects of TRIPS-mandated intellectual property rights on economic activities in developing countries | |
| Joshi et al. | Does it pay to deliver? An evaluation of India’s safe motherhood program | |
| CN114255877A (en) | Target point information mining and searching method and device, electronic equipment and storage medium | |
| Chandra et al. | Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation | |
| CN114358939B (en) | Monitoring method and device for hot spot information in pharmaceutical industry, electronic equipment and storage medium | |
| Bravo et al. | Understanding pharmaceutical sustainable supply chains–a case study application | |
| Huić et al. | Collaboration in health technology assessment (EUnetHTA joint action, 2010–2012): four case studies | |
| CN113674867A (en) | Clinical data mining method and device, electronic equipment and storage medium | |
| Cingolani et al. | Administrative capacities that matter: organisational drivers of public procurement competitiveness in 32 European countries | |
| Dorward et al. | PROTOCOL: Agricultural Input Subsidies for improving Productivity, Farm Income, Consumer Welfare and Wider Growth in Low‐and Middle‐Income Countries: A Systematic Review | |
| Buccafusco et al. | The Price of Fairness | |
| CN116433179A (en) | Database-based public bidding information standardization method | |
| Trappey et al. | Collective intelligence applied to legal e-discovery: A ten-year case study of Australia franchise and trademark litigation | |
| West et al. | Finance and incentives to support the development of national pharmaceutical industries | |
| Verevka et al. | Digital transformation of the Russian agricultural sector: technological and economic barriers | |
| Khadim et al. | Influence of record keeping on the performance of micro and small enterprises in the context of their area of operation: An empirical study | |
| Sukma et al. | Exploring The Effect Of State-Owned Enterprise Corporate Social Responsibility On Small Medium Enterprise Digitalization In Indonesia | |
| CN113094407B (en) | Anti-money laundering identification method, device and system based on horizontal federal learning | |
| Liu | Deregulation on branded and generic drugs price and its effect: a study of Chinese pharmaceutical market | |
| Sultanow et al. | E-commerce Adoption: A Revelatory Case Study in the German Oncology Pharmaceutical Supply Chain' | |
| Raventos et al. | Electronic procurement of pharmaceuticals and medical devices in chile: an initial empirical investigation | |
| Huang | Maximizing Chinese Imports' Compliance with United States Safety and Quality Standards: Carrot and Stick from Whom | |
| Cohrssen | FDA Reform: Deja Vu Encore | |
| CN118037330A (en) | Method, device, computer equipment and storage medium for retrieving bid-winning information of medicine | |
| Yue et al. | clinical meaningfulness of duloxetine’s effect in chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |